SpyGlass Pharma Stock Price, News & Analysis
Company Description
SpyGlass Pharma (NASDAQ: SGP) is a publicly traded biotechnology company in the Surgical & Medical Instruments & Apparatus sector. The company has a market capitalization of $744.2M, ranking #3,240 among all listed U.S. companies by market cap.
SGP stock has declined 26.3% over the past year, placing it at #3,908 in year-to-date performance among tracked companies. Shares last traded at $19.47.
On a trailing twelve-month basis, SpyGlass Pharma reported net income of -$39.9M and diluted earnings per share of $-17.98.
This page provides a comprehensive overview of SGP stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
SpyGlass Pharma (SGP) stock last traded at $19.47, down 2.52% from the previous close. Over the past 12 months, the stock has lost 26.3%. At a market capitalization of $744.2M, SGP is classified as a small-cap stock with approximately 33.4M shares outstanding.
SGP Rankings
Latest News
SpyGlass Pharma has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. Key topics include conferences, earnings, clinical trial, IPO, offering. View all SGP news →
SEC Filings
SpyGlass Pharma has filed 5 recent SEC filings, including 3 Form 8-K, 1 Form 10-Q, 1 Form 10-K. The most recent filing was submitted on May 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all SGP SEC filings →
Financial Highlights
operating income reached -$41.4M, and net income was -$39.9M. Diluted earnings per share stood at $-17.98. The company generated -$32.7M in operating cash flow. With a current ratio of 12.67, the balance sheet reflects a strong liquidity position.
Upcoming Events
Phase 3 enrollment completion
Phase 3 enrollment completion
SpyGlass Pharma has 2 upcoming scheduled events. The next event, "Phase 3 enrollment completion", is scheduled for January 1, 2027 (in 182 days). Investors can track these dates to stay informed about potential catalysts that may affect the SGP stock price.
Short Interest History
Short interest in SpyGlass Pharma (SGP) currently stands at 1.0 million shares, down 11.6% from the previous reporting period, representing 5.3% of the float. Over the past 12 months, short interest has increased by 458.9%. With 14.3 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for SpyGlass Pharma (SGP) currently stands at 14.3 days, down 26.4% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 1211.9% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 1.1 to 19.4 days.
SGP Company Profile & Sector Positioning
SpyGlass Pharma (SGP) operates in the Biotechnology industry within the broader Surgical & Medical Instruments & Apparatus sector and is listed on the NASDAQ. In monthly performance, the stock ranks #3,548 among all tracked companies.